TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
4.050
-0.070 (-1.69%)
Nov 21, 2024, 1:03 PM EST - Market open
TScan Therapeutics Revenue
TScan Therapeutics had revenue of $1.05M in the quarter ending September 30, 2024, a decrease of -73.01%. This brings the company's revenue in the last twelve months to $9.36M, down -44.71% year-over-year. In the year 2023, TScan Therapeutics had annual revenue of $21.05M with 55.52% growth.
Revenue (ttm)
$9.36M
Revenue Growth
-44.71%
P/S Ratio
23.48
Revenue / Employee
$60,792
Employees
154
Market Cap
216.15M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 21.05M | 7.51M | 55.52% |
Dec 31, 2022 | 13.54M | 3.39M | 33.47% |
Dec 31, 2021 | 10.14M | 9.06M | 834.65% |
Dec 31, 2020 | 1.09M | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
High Tide | 370.02M |
Inogen | 331.52M |
biote | 193.06M |
Sutro Biopharma | 160.96M |
Genfit | 86.23M |
Utah Medical Products | 44.08M |
Zentalis Pharmaceuticals | 40.56M |
aTyr Pharma | 235.00K |
TCRX News
- 16 days ago - TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition - GlobeNewsWire
- 6 weeks ago - TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting - GlobeNewsWire
- 3 months ago - TScan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology - Seeking Alpha
- 3 months ago - TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - TScan Therapeutics Announces Updates to its Board of Directors - GlobeNewsWire
- 6 months ago - TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 6 months ago - TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies - GlobeNewsWire